3H-imipramine binding in 39 drug@freepatients with major depression and 44 healthy controls did not differ significantly between the two groups, in male or female subjects or in subgroups of depressed patients divided by endogenicity or dexamethasone suppression test result. 3H-imipramine binding in depressed patients drug-free for less than three weeks did not differ from those drug-free for longer intervals or from controls. A significant seasonal variation of 3H-imipramine Bmax was found, with lower valuesin summerand autumn. Treatment of depressedpatients with imipramineor lofepraminefor six weeks increasedKD and Bmax. Methodological modification(inpreparationandstorageof platelets)doesnot explainthe major differencesin resultsbetweenthisstudy (usingfrozenplatelets),a previousone (usingfreshly preparedplatelets)andothersin general,althoughit might contributeto the rangeof values reported.
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Specific high-affinity binding sites for 3H-imipramine (3H-IMIP) are associated with the serotomn uptake mechanism in neurones and platelets (Langer et a!, 1982) .Initial studies reported markedly lower numbers of platelet 3H-IMIP binding sites (reduced Bmax) in depressed patients compared with controls (Briley et al, 1980; Raisman et a!, 1981, 1982) . Some subsequent studies have replicated these findings (Poirier eta!, 1986; Innis eta!, 1987; Maj eta!, 1988) , others have reported less marked but statistically significant reductions (Lewis & McChesney, 1985; Wagner et al, 1985) and an increasingnumber have found no significant differences betweendepressed patients and controls (Oentsch et a!, 1985 The discrepanciesbetween studiescast doubts on the validity of reducedplatelet 3H-IMIP as a useful biological marker of depressionand therefore it is important to attempt to identify the factors which contribute to the inconsistencies.Subject selection may be important. The depressedpatients studied have varied widely in their severity and symptoms. Somestudiessuggestthat reducedBmax of platelet 3H-IMIP binding is associated with certain sub groupsof depressed patients, for examplethosewith a positive family history of depression (Lewis & McChesney, 1985; Schneider et a!, 1986) Seasonal variations in platelet 3H-IMIP binding, although inconsistentlyreported, may also influence results. Furthermore, methodological differences may contribute to both the discrepanciesbetweenstudies in depressionand the large variations in equilibrium dissociation constants (KD) and number of binding sites (Bmax) values reported for control subjects between laboratories (Mellerup & Plenge, 1988) . For example, platelets have been isolated by different methods, and whole plateletsand membranes,from freshlypreparedand previouslyfrozen platelets,have been studied.
We have recently reported a study of 3H-IMIP binding in a large group of depressed patients (Theodorou eta!, 1989) .Plateletswereisolated and platelet membranes prepared and assayedon the same day. We found that overall 3H-IMIP Bmax did not differ significantlybetweendepressed patients and controls. Therewasa small(14Â¾) but significant reduction in female depressedpatients, but not in males. Lower 3H-IMIP Bmax was not associated with endogenicity, dexamethasonesuppressiontest result, family history of depression, depressive psychosis,suicideideation or past history of suicide attempts. 3H-IMIP Bmax was however lower in those depressedpatients with obsessionalfeatures. The reconstitution with normal salineand centrifugation wererepeatedone further time. The original platelet-rich plasma and the saline supernatantswere combined and centrifuged at 1500g for 15miii. The supernatant wasdis. carded, the platelet pellet rapidly frozen by immersion in adry-icealcoholmixtureandstoredat â€"¿ 80Â°C until assayed. On the day of assay,5 ml of washing buffer (50mM TRIS-HC1(tris(hydroxymethyl)aminomethane-hydrochlonc acid), 110mM sodium chloride (NaCl), 20mM ethylene diamunetetra-acetic acid(EDTA),pH 6.4)wasadded to the platelet pelletsand the plateletsuspensionstood on ice for 5 miii beforebeinghomogenised (sixstrokes,teflon in glass, motor driven at 800r.p.m.) and centrifugedat 18500g for 10mm. The supernatant was discarded and the pellet homogenisedand centrifuged as above. The supernatant was discardedand the pellet homogenised(12 strokes at 1200 r.p.m.) in hypotonic lysing buffer (5 mM tris-HC1, 5 mM EDTA, pH 7.4), allowedto standon ice for 20 mm, and centrifuged at 42 000g for 10mm. The pellet was suspendedin incubation buffer (50mM tris-HC1, 120mM NaCl, 5 mM potassium chloride (KC1), pH 7.5) and centrifugedat 42000g for 10miii. The resultingpelletwas resuspended in incubation buffer (to give 50â€"70 @g protein/assaytube)andincubatedwith nineconcentrations (0.2-6 nM) of 3H-IMIP (specificradioactivity20Ci/mmol) for 75 mm at 0Â°C in a volume of 0.5 ml. Specificbinding was defined as radioactivity displaced by l0-@M des methylimipramine. Membrane-bound radioactivity was recoveredby filtration under reduced pressurethrough Whatmanglass-fibre(GF/C) filters, presoaked in 0.5% polyethylenimine to reduce non-specific filter binding. Filters were washed (four times, 4 ml) with ice-cold incubation buffer, placedin scintillation vials containing 6 ml of PackardES299scintillation cocktail and counted at an efficiency of 38â€"45%. Samples from depressed patientsand controls wereassayedconcurrently. Aliquots of membrane were stored at â€"¿ 20Â°Cbefore protein determination by the method of Lowry eta! (1951)using bovine serum albumen as a standard.
3H-IMLPRAMINEBINDING TO DEPRESSIVES' PLATELET MEMBRANES
Both Bmax and KD were determinedby computerised non-linear fitting (usinga commercialpackage,Statistical Analytical Systems,1982) to saturation plots.
Dexamethasonesuppression test (DST)
Dexamethasone(1 mg)wasadministeredorally to depressed patients at 20:00hours on the sameday as the baseline blood sample for platelet 3H-IMIP binding was taken. Blood (10ml) was taken by antecubital venepunctureat 15:30hours on the following day, placedin a heparinised tube and immediately centrifuged at 4000g for 4 mm.
We now report a further study of platelet 3H-IMIP binding in which we have addressedthe effects of platelet isolation and storage in a new cohort of depressedpatients and controls. Two aspects of our previous methodology were altered.
Firstly, platelet isolation was modified to increase platelet yield and to increase recovery of heavy platelets. Secondly, platelets were stored frozen before assay,to allow a more direct comparisonwith the majority of published studies.
Method
Depressed patientswererecruitedfrom in.patients (n = 28) at the Professorial Unit, Fulbourn Hospital, Cambridge or out-patients (n = 11)attending the Affective Disorders Clinic, Addenbrooke'sHospital, CambridgebetweenJune 1986and December1987.Patients were enteredinto the study, subject to their informed written consent, if they fulfilled the following criteria: (1) ResearchDiagnostic Criteria (RDC; Spitzer & Endicott, 1978) for major depressivedisorder, probable or definite, or for bipolar depression;(2) a minimum score of 17 on the 17-item Hamilton Rating Scale for Depression (HRSD; Hamilton,
1967);
(3) no major physical illness; (4) at least seven days free of antidepressant drugs and at least six months free from neuroleptics. Particular efforts were made to recruit patients who were antidepressant-free for six weeksor more. A number of patientscontinued to receive short-acting benzodiazepinesfor night-time sedation.
Controls wererecruitedover the sametime period from among the staff of the psychiatric servicesand their acquaintances. Theyhadno physicalor psychiatricillnesses and were free of psychoactivedrugs.
Psychiatric assessments
Theseincluded: (1) detailed demographic, social, family and past psychiatric history questionnaires;(2) ratings of depressiveseverity using the HRSD and the Clinical Interview for Depression (CID; Paykel, 1985) ; (3) 
Theseassessmentswerecarriedout at baseline,and HRSD
and CID were repeatedafter six weeksof treatment.
Treatment
Patientsweretreated for up to six weekswith imipramine (150-225 mg/day), lofepramine (140-210 mg/day) or electro convulsive therapy (ECT). It was not possibleto obtain post-treatment results on all patients as some required additional treatment to the above, someleft care and, in a small number of cases,assayswere unsuccessful. t-tests (three groups) or Gabriel's test (more than three groups).
Results
The clinical featuresof the depressedpatients are shown in Table I .
Comparison between depressed patients and controls
Bmax and KD of 3H-IMIP binding did not differ signifi cantly betweencontrols and depressed patientsin the total group or when divided by sex (Table II) or in the female subjectspre-or post-menopausally(data not shown).
Comparison between depressive subgroups and controls
BmaxandKDof 3H-IMIP bindingdid not differ signifi cantlybetween NDS-or RDC-defmed endogenous andnon endogenous subgroups (TableII) andDST suppressors or non-suppressors (TableIII) or between these subgroups and controls in the total sampleand in female subjects.
Specificclinical features
Depressedsubjectswere divided in terms of past history of suicideattempts, serioussuicideattempts and current suicidal intent, obsessionalfeatures (HRSD and CID), diurnal mood variation (HRSD and CID), weight loss (HRSD) reactivityof mood (CID) and depressive delusions (CID). Depressed patientswith highscores on suicideideation andthosewhohada pasthistoryof attemptedsuicideor Plasmawasfrozenat â€"¿ 20Â°C beforecortisol determination by radio-immunoassayusing a commercial kit (Amerlex, Amersham International, UK). Non-suppression wasdefmed asa post-dexamethasone cortisolof @ 5 @&g/dl. The DST was not performed on out-patients.
Statistical analysis
Bmaxvaluesapproximatedto a normaldistribution. KD values approximated to a normal distributionfollowinglog transformation, hencestatistical testson KD valueswere carried out using log transformed data. Differences between pairs of meanswere compared by Student's t-test (two tailed, unpairedexcepttwo-tailed, paired wasusedfor the effectsof treatment).For multiple comparisons, theoverall differences between means were first compared using F-testson the one-way analysisof variance, followed by 
Effects of treatment
Treatment was associated withasignificant increaseinBmax (TableIV). In depressed patientstreatedwithimipramine (n=10) or lofepramine (n=6) increases in bothBmaxand K,, were found, althoughfor eachdrug the difference failed to reach statistical significance (Table IV) .
Effects of season
Subjects were divided by season of testing. A significant seasonalvariation in Bmax was seen in controls and depressedpatients,withlowvaluesin summerand autumn (Table V) . The seasonal variation in Bmax wasof similar magnitude in male and female subjects (Table VI) 
Discussion
In the present study we have examined â€˜¿ H-IMIP binding in a second large cohort of depressedpatients and controls. The same subject selection criteria were applied as in our previous study (Theodorou et a!, 1989 )and although subjects were recruited from a different geographical area, the two populations were very similar both in their demographic characteristics and in the nature, severity and clinical features of their depression. Thus, differences between our presentand previousfmdings (Theodoroueta!, 1989) are likely to have arisen because of methodological factors, rather than differences in the subjects.
Two aspectsof methodology werealtered. Differ encesin platelet recovery may in part explain the Thus platelet-rich plasmawaspreparedby a method which maximises platelet yield and, in particular, recovers heavier platelets. The other difference from our previous study was that platelets were stored frozen before assay. We thought this might be import ant sinceour Bmax valuesin freshlypreparedplatelets werehigher than thosereported for frozen platelets.
Bmax values in controls were significantly lower than those we reported for fresh platelets (Bmax, 1668 fmol/mg protein; Theodorou eta!, 1989). The substantial difference between fresh and frozen platelets seemsunlikely to be attributable to platelet preparation, since the presumed greater yield of heavier platelets would be expected to increase, rather than decrease, â€˜¿ H-IMIP Brnax (Arora & Meltzer, 1984) . The difference in Bmax may be related to freezing and/or storage of platelets before assay. Bmax values for controls in the present study were within the range reported for frozen platelets in some studies ( K,, values have also differed widely between studies. Our K,, values in frozen platelets were lower than many others reported and lower than thosewe reported in fresh platelets. Mellerup & Plenge (1988) recently reviewed studies of platelet â€˜¿ H-IMIP binding in depression and concluded that under optimal assay conditions, KD values should be 0.5 nM, close to the value of 0.56 nM that we found. Higher KD values (lower binding affinity) are a reflection of non optimal conditions. They commentedthat of the 19 studiesthat reported a significant reduction in Binax in depression,84Â¾ reported KD valuesgreaterthan 1nM while of 11studiesthat reported no difference in Bmax in depression only 45% had KD values greater than 1nM (Meilerup & Plenge, 1988) . Increases in platelet â€˜¿ H-IMIP binding have previously been reported in depressed patients following treatment with zimelidine, alaproclate and desipramine (Wagner et a!, 1987; Arora & Meltzer, 1988) ,and in healthy volunteers following administration of amitriptyline and desipramine (Braddocketa!, 1984; Coweneta!, 1986; Healy eta!, 1990) . In the present study, there were significant increases in KD and Bmax of 3H-IMIP binding in patients treated with imipramine or lofepramine for six weeks. This effect may not be common to all antidepressants. Short-term administration of depressant-free for lessthan threeweeksalsodid not differ significantly from thosepatientsdrug-free for longer intervals or from controls. The majority of thesepatients were drug-free for betweentwo and three weeks (all were drug-free for a minimum of sevendays) and this may have beensufficient time for residualeffectsof previousantidepressantsto be no longer apparent.
Several studieshavereportedno seasonal variation in â€˜¿ H-IMIP binding (Carstenset a!, 1986; Galzin et a!, 1986) , while others have reported significant, although varied, seasonaldifferences (Whitaker et a!, 1984; Hrdina eta!, 1985; Egriseeta!, 1986; Kanof et a!, 1987) . Although the present study was not specifically designed totest forseasonal variations, we found significantly lower Bmax valuesin summer and autumn; an effect apparent in controls and depressedpatients and in male and female subjects.
These findings are similar to those reported by Whitaker eta! (1984) . It is possible that differences betweencontrols and depressedpatients could arise or be maskedartefactually by the seasonof testing. However, this seemsunlikely since controls and As in our previous study we found no overall difference in KD or Bmax of 3H-IMIP binding between controls and depressedpatients. The small but significantly lower number of 3H-IMIP binding sites we previously reported in female depressed patients was not apparent (Theodorou et a!, 1989) . We haveexaminedpossiblerelationshipsbetween 3H-IMIP binding and specific clinical symptoms within depressed patients.No relationshipwasfound with weight loss, reactivity of mood and depressive delusions.Serioussuicideattemptsand diurnal mood variation were associatedwith increasedand decreased 3H-IMIP Bmax respectively, although in neither case were Bmax values in the presence or absence of the symptomdifferent from control values.In our previousstudyno relationshipwasidentified between thesesymptoms and â€˜¿ H-IMIP Bmax. However, in that study we did find that depressed patients with marked obsessionalfeatures had lower Binax than both patients without such symptoms and controls. The present study did not replicate this finding; the tendency was in the opposite direction.
Thus, although the presentand our previous study (Theodorou eta!, 1989) have each identified relation shipsbetweenspecificsymptomsand 3H-IMIP Bmax that satisfycriteria of statisticalsignificance,the lack of replication betweenstudiescastsdoubts on their importance. patients were recruited throughout the whole period of the study and, apart from some mismatch in the summer, were reasonably matched for season of testing.
Modifications in methodology indicate that although platelet preparation and storage affect â€˜¿ H-IMIP binding and thus contribute to the wide range of reported values, they do not explain the major differences between studies of depressed patients and controls. Our present and previous studies (Theodorou et a!, 1989) , in two separate patient and control populations totalling 86 patients and 90 controls, found no difference overall in KD or Bmax of 3H-IMIP binding in depression, and no reproducible relationship betweenreduced â€˜¿ H-IMIP Binax and the major categorical variables of endogenicity and DST or with specific symptoms.
A biological marker for depression should be demonstrable and quantitatively reproducible between studies and between laboratories, allowing for diagnostic variability. Although some reports of 3H-IMIP binding relate to rather small numbers of subjects and thus may lack the statistical power necessaryto detect small differences between controls and depressed patients, there are now sufficient studies, with adequate numbers of subjects, to doubt the validity of marked reductions in platelet â€˜¿ H-IMIP binding in depression.Although the poss ible associationof reducedBmax with selectedsub groups of depressedhas some support, as yet such factors havenotbeenclearly orconsistently identified.
